Business
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at
About this update from Disc Medicine, Inc.
[{"type":"text","content":"Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at both development and commercial-stage companiesJonathan Yu, previously Chief Business Officer at Disc, has been promoted to Chief Operating Officer WATERTOWN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Jean Franchi as the company’s Chief Financial Officer. Ms. Franchi will be responsible for finance, investor relations, and other functions and will lead the company’s capital formation and financial strategy. She succeeds Joanne Bryce, who will transition to a consulting role with the company. “We are excited to welcome an executive of Jean’s caliber and depth of experience to the Disc team, and I’m delighted to announce the promotion of a key executive, Jonathan Yu, to Chief Operating Officer,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “We have multiple, important data read-outs for all three programs in 2024, and as we enter late-stage development and begin planning for commercialization, Jean’s experience with successfully scaling organizations, including those focused on rare diseases, will be directly relevant. On behalf of myself and the entire Disc team, I would also like to express my gratitude to Joanne for her leadership and years of service and wish her all the best on her next endeavor.” “I am thrilled to be joining Disc at such an exciting moment in its evolution. The team has built a unique company with a strong foundation and pipeline with enormous potential,” said Ms. Franchi. “I look forward to working together with the talented and passionate people at Disc to build a sustainable, leading hematology business.” Ms. Franchi is an experienced CFO with over 30 years of finance leadership expertise at both public and private biotechnology companies of varying sizes across all stages of development. Most recently, she was the Chief Financial Officer of Replimune where she helped raise over $750 million across multiple financings and non-dilutive debt, supporting significant expansion w...